Add-On tolterodine extended release improves overactive bladder symptoms in men receiving alpha-blocker therapy

被引：0
作者：
Chapple, C. [1 ]
Abrams, P. [2 ]
Herschorn, S. [3 ]
Sun, F. [4 ]
Brodsky, M. [5 ]
Guan, Z. [5 ]
机构：
[1] Royal Hallamshire Hosp, Dept Urol, Sheffield S10 2JF, S Yorkshire, England
[2] Bristol Urol Inst, Dept Urol, Bristol, Avon, England
[3] Univ Toronto, Dept Urol, Toronto, ON, Canada
[4] Pfizer Inc, Dept Stat, New York, NY USA
[5] Pfizer Inc, Dept Med Urol, New York, NY USA
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2008年 / 7卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
671
引用
收藏
页码：239 / 239
页数：1
相关论文
共 50 条
[31]   Is There Any Objective Improvement of Nocturia by Combination Treatment of Zolpidem and Alpha-Blocker Therapy for Unresponsive to Alpha-Blocker Monotherapy in Men with Lower Urinary Tract Symptoms? [J].
Doo, Seung Whan ;
Kim, Jae Heon ;
Yang, Won Jae ;
Song, Yun Seob .
LUTS-LOWER URINARY TRACT SYMPTOMS, 2013, 5 (03) :134-139
[32]   The effect of vibegron as add-on therapy to alpha 1-blocker on the sexual function and overactive bladder symptom in patients with benign prostatic hyperplasia [J].
Yanagida, Kazuki ;
Watanabe, Daisuke ;
Yoshida, Takahiro ;
Nakagawa, Tohru ;
Mizushima, Akio .
INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 :36-36
[33]   Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial [J].
Roberts, R. ;
Bavendam, T. ;
Glasser, D. B. ;
Carlsson, M. ;
Eyland, N. ;
Elinoff, V. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (06) :752-758
[34]   Efficacy and safety of add-on mirabegron vs placebo to tamsulosin in men with overactive bladder symptoms (match study) [J].
Lee, K-S. ;
Kakizaki, H. ;
Yamamoto, O. ;
Jong, J. J. ;
Katou, D. ;
Sumarsono, B. ;
Uno, S. ;
Yamaguchi, O. .
INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 :65-65
[35]   Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials [J].
Wu, Yonglu ;
Li, Guanjun ;
Zhou, Haimin ;
Wu, Aiming ;
Tan, Guobin ;
Huang, Shuitong ;
Chen, Guangming ;
Chen, Xianxi ;
Li, Zhiqin .
UROLOGIA INTERNATIONALIS, 2024, 108 (02) :118-127
[36]   Identifying patients with benign prostatic hyperplasia with overactive bladder and determining the efficacy of combination therapy with alpha blocker and tolterodine [J].
Lee, JY ;
Jung, JH ;
Ko, JS .
JOURNAL OF UROLOGY, 2003, 169 (04) :477-477
[37]   Role of Bladder Dysfunction in Men with Lower Urinary Tract Symptoms Refractory to Alpha-blocker Therapy: A Video-urodynamic Analysis [J].
Jiang, Yuan-Hong ;
Liao, Chun-Hou ;
Kuo, Hann-Chorng .
LUTS-LOWER URINARY TRACT SYMPTOMS, 2018, 10 (01) :32-37
[38]   Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor: A Preliminary Study [J].
Ishikawa, Keisuke ;
Tsujimura, Akira ;
Miyoshi, Miho ;
Miyoshi, Yuto ;
Ogasa, Taiki ;
Hiramatsu, Ippei ;
Uesaka, Yuka ;
Nozaki, Taiji ;
Shirai, Masato ;
Mitsuhashi, Isao ;
Sugimura, Sosuke ;
Mizuno, Taiki ;
Noto, Kensho ;
Shigeta, Yasuhiro ;
Honda, Shinichi ;
Iwata, Shinji ;
Horie, Shigeo .
UROLOGY, 2021, 153 :256-263
[39]   MIRABEGRON VS. PLACEBO ADD-ON THERAPY IN MEN WITH OVERACTIVE BLADDER SYMPTOMS RECEIVING TAMSULOSIN FOR UNDERLYING BENIGN PROSTATIC HYPERPLASIA: A SAFETY ANALYSIS FROM THE PLUS STUDY [J].
Herschorn, S. ;
McVary, K. ;
Cambronero Santos, J. ;
Foley, S. ;
Kristy, R. ;
Choudhury, N. ;
Hairston, J. ;
Kaplan, S. .
NEUROUROLOGY AND URODYNAMICS, 2019, 38 :S175-S177
[40]   Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE) [J].
Drake, Marcus J. ;
MacDiarmid, Scott ;
Chapple, Christopher R. ;
Esen, Adil ;
Athanasiou, Stavros ;
Cambronero Santos, Javier ;
Mitcheson, David ;
Herschorn, Sender ;
Siddiqui, Emad ;
Huang, Moses ;
Stoelzel, Matthias .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (05)
12345